These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22171470)

  • 41. Respiratory syncytial virus bronchiolitis in children.
    Verger JT; Verger EE
    Crit Care Nurs Clin North Am; 2012 Dec; 24(4):555-72. PubMed ID: 23089660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiviral antibodies in transplantation.
    Snydman DR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):10-2. PubMed ID: 7482809
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Possibilities and perspectives of the prevention of viral hepatitis].
    Fehér J; Lengyel G
    Orv Hetil; 1997 Jun; 138(22 Suppl 1):1482-6. PubMed ID: 9221378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment and prevention of viral infections (HSV, CMV, HPV, HBV).
    Amstey MS
    Clin Obstet Gynecol; 1988 Jun; 31(2):501-9. PubMed ID: 2841054
    [No Abstract]   [Full Text] [Related]  

  • 46. Guidelines for the use of palivizumab in infants and young children with congenital heart disease.
    Nakazawa M; Saji T; Ichida F; Oyama K; Harada K; Kusuda S
    Pediatr Int; 2006 Apr; 48(2):190-3. PubMed ID: 16635185
    [No Abstract]   [Full Text] [Related]  

  • 47. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study.
    Gaboli M; de la Cruz ÒA; de Agüero MI; Moreno-Galdó A; Pérez GP; de Querol MS
    Pediatr Pulmonol; 2014 May; 49(5):490-502. PubMed ID: 23775884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Passive immunity in prevention and treatment of infectious diseases.
    Keller MA; Stiehm ER
    Clin Microbiol Rev; 2000 Oct; 13(4):602-14. PubMed ID: 11023960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunoglobulins in virological research and in the prevention of infections].
    Pshenichnov VA; Krasnianskiĭ VP; Mikhaĭlov VV
    Vopr Virusol; 1992; 37(4):178-80. PubMed ID: 1471338
    [No Abstract]   [Full Text] [Related]  

  • 50. The growth and potential of human antiviral monoclonal antibody therapeutics.
    Marasco WA; Sui J
    Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.
    Walker LM; Burton DR
    Nat Rev Immunol; 2018 May; 18(5):297-308. PubMed ID: 29379211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Achievements and challenges in antiviral drug discovery.
    Littler E; Oberg B
    Antivir Chem Chemother; 2005; 16(3):155-68. PubMed ID: 16004079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of differential antiviral immunity in children and adults.
    Prendergast AJ; Klenerman P; Goulder PJ
    Nat Rev Immunol; 2012 Sep; 12(9):636-48. PubMed ID: 22918466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.
    Bregenholt S; Jensen A; Lantto J; Hyldig S; Haurum JS
    Curr Pharm Des; 2006; 12(16):2007-15. PubMed ID: 16787244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In response to the letter from Braden.
    Meissner HC; Hennessy S; Rowe E; Brady MT
    Pediatrics; 2014 Dec; 134(6):e1783-4. PubMed ID: 25452651
    [No Abstract]   [Full Text] [Related]  

  • 56. Re: technical report.
    Braden NJ
    Pediatrics; 2014 Dec; 134(6):e1781. PubMed ID: 25452649
    [No Abstract]   [Full Text] [Related]  

  • 57. Authors' responses in response to the letter from Ambrose.
    Meissner HC; Brady MT; Byington CL; Kimberlin DW; Lieberthal AS; Maldonado YA; Ralston SL; Winterstein A
    Pediatrics; 2014 Dec; 134(6):e1782-3. PubMed ID: 25452650
    [No Abstract]   [Full Text] [Related]  

  • 58. Guidelines for laboratory monitoring of treatment of persistent virus infections.
    Pillay D; Emery VC; Mutimer D; Ogilvie MM; Carman W; Mutton K; Wreghitt T; Westmoreland D; Breuer J; Zuckerman M;
    J Clin Virol; 2002 Jul; 25(1):73-92. PubMed ID: 12126724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
    Chaudhuri S; Symons JA; Deval J
    Antiviral Res; 2018 Jul; 155():76-88. PubMed ID: 29758235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TNFalpha antagonist therapy in patients with joint disease and chronic viral infection.
    Wendling D; Herbein G
    Joint Bone Spine; 2007 Oct; 74(5):407-9. PubMed ID: 17644391
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.